Summary.
Over the years, methods of cytogenetic analysis evolved and became part of routine laboratory testing, providing valuable diagnostic and prognostic information in hematologic disorders. Karyotypic aberrations contribute to the understanding of the molecular pathogenesis of disease and thereby to rational application of therapeutic modalities. Most of the progress in this field stems from the application of metaphase cytogentics (MC), but recently, novel molecular technologies have been introduced that complement MC and overcome many of the limitations of traditional cytogenetics, including a need for cell culture. Whole genome scanning using comparative genomic hybridization and single nucleotide polymorphism arrays (CGH-A; SNP-A)
can be used for analysis of somatic or clonal unbalanced chromosomal defects. Depending on the density of arrays, its resolution allows for detection of microdeletions and duplications. In SNP-A combination of copy number detection and genotyping enables diagnosis of copy-neutral loss of heterozygosity, a lesion that cannot be detected using MC but may have important pathogenetic implications. Overall, whole genome scanning arrays, despite the drawback of an inability to detect balanced translocations, allow for discovery of chromosomal defects in a higher proportion of patients with hematologic malignancies. Newly detected chromosomal aberrations, including somatic uniparental disomy, may lead to more precise prognostic schemes in many diseases.
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Routine cytogenetics diagnostics and its limitations
Cytogenetic analysis has provided fundamental insights into the molecular pathogenesis of a variety of hematological disorders. The discovery of the Philadelphia chromosome and other chromosomal aberrations paved the way for the characterization of molecular lesions that lead to phenotypic characteristics of a number of hematological malignancies. Metaphase cytogenetics (MC) has proven an extremely valuable diagnostic tool, providing definite diagnoses, e.g., in the case of balanced pathognomonic translocations in chronic myeloid leukemia (CML), acute promyelocytic leukemia (APL) or core binding factor acute myelogenous leukemias (AML) 1;2 .
Chromosomal aberrations support the cyto-morphologic diagnosis and provide prognostic information, for example, in myelodysplastic syndromes (MDS) [3] [4] [5] , AML with unbalanced translocations [6] [7] [8] [9] [10] , multiple myeloma (MM) 11;12 and chronic lymphocytic leukemia (CLL) 13;14 .
Irrespective of their location, size and corresponding phenotype, chromosomal defects also represent suitable markers of clonality suggestive of clonal dominance by the malignant clone or, in rare circumstances, of oligoclonality due to a profound depletion of stem cell reserves 15 ( Figure   1 ). Such a scenario explains the occasional occurrence of chromosomal abnormalities in otherwise typical aplastic anemia (AA) 16 .
Technical advantages and limitations of MC. Routine MC allows for detection of large
clonal populations (>10% of dividing cells) indicating the presence of significantly expanded and dominant clones [17] [18] [19] [20] . Moreover, multiple clones may be detected and can be distinguished from complex karyotypic lesions occurring within a single clone.
Many invariant chromosomal lesions affect the behavior of malignant clones, their progression, response to therapy and patient survival. This information has been incorporated in predictive schemes in various hematologic malignancies. For example, the International Prognostic Scoring System (IPSS) for MDS provides an algorithm that is predominantly based on the types of cytogenetic lesions 21 .
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Chromosomal abnormalities are present only in a proportion of cases including, e.g., 50%
of MDS or AML and to a lesser extent in other myeloid malignancies. This inability to detect lesions may be due to the relatively low resolution of MC, estimated to be 1-10Mb [17] [18] [19] [20] . While a normal MC result by itself tends to indicate a more favorable prognosis, there is great clinical diversity within patients with normal MC and this large group cannot be further stratified using cytogenetics as a parameter. In addition, reliance on cell division leaves a significant proportion of cases unresolved due to lack of growth or specimen hypocellularity. Theoretically, cryptic clonal lesions are present in many, if not most cases of AML, MM and MDS, but cannot be detected due to their size or due to technical shortcomings of MC. Such additional "hidden" lesions may also exist in patients with known abnormalities, further contributing to clinical heterogeneity and modifying the prognosis assigned to known invariant aberrations. Moreover, smaller chromosomal changes may allow for better mapping of causative genes in commonly deleted regions (CDR).
New cytogenetic methods.
Increased sensitivity and resolution are likely to improve the diagnostic value of cytogenetic diagnostics. Various karyotypic methods have been introduced, including spectral karyotyping (SKY) and fluorescent in situ hybridization (FISH). To date, only FISH is routinely applied for targeted detection of specific lesions with established clinical relevance 22 . However, as in the case of unbalanced translocations, the increased sensitivity of FISH for unbalanced chromosomal defects is difficult to translate into prognostic information. For example, the presence of a small proportion of abnormal cells may simply indicate that hematopoiesis is not entirely clonal.
Moreover, if the difference between the "background" intrinsic to the technique seen in otherwise normal bone marrow and the size of the abnormal clone in a patient is small, its relevance may not be clear. However, due to the speed and ease of application and lack of reliance on cell growth, FISH is widely applied as a reliable diagnostic tool in the search for specific balanced translocations 22 . Clinical FISH is performed on interphase cells, including more mature non-dividing 4 only.
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DNA whole genome scanning technology using DNA arrays. Areas known to contain more SNPs can be better covered while, as expected, the resolution within "SNP deserts" is poor.
Chip-and bead-based platforms of SNP-A are available. In the technology utilized by Affymetrix, genomic DNA is digested by restriction endonucleases, amplified and labeled.
Following hybridization to the arrays, a read-out can be generated that includes genotyping calls.
Furthermore, the strength of the hybridization signal corresponds to the copy number of the genomic region (Figures 2 & 3) . In bead-based platforms, the whole genome amplification and For personal use at PENN STATE UNIVERSITY on February 27, 2013. bloodjournal.hematologylibrary.org From (frequency of heterozygous calls) and determination of hybridization intensity, a feature which allows for reduction of the variability of results 25;27 (Figure 4) . Analysis of these two parameters increases the precision of copy number determination 25;27 . The data output can be generated using several biostatistical and genetic software packages based on various bioanalytical principles; one excellent example of such an algorithm is CNAG 24;28 that combines copy number analysis and LOH
(Figures 4 & 5).
Higher density arrays provide a greater resolution that can be further increased by inclusion of sequential oligonucleotide probes which do not depend upon the presence of SNPs. SNP-A allow for assessment of the gene copy number-neutral LOH, such as autozygosity or uniparental disomy (UPD) 26 . To increase resolution, arrays containing both SNP and genomic probes are now available; various combinations of tagging, non-synonymous and copy number variants (CNV)
probes can be included in such mixed SNP/oligonuclotide copy number probe arrays, which combine the advantages of SNP-A and some of the advantages of CGH-A (see below).
Comparative genomic hybridization arrays (CGH-A).
In contrast to SNP-A and oligo A, CGH-A relies on the difference in the copy number between test and reference DNA samples and is based on dual color labeling of test and reference control DNA (Figure 2 Resolution depends on the density of the arrays, distribution of probes and biostatistical algorithms used to detect copy number changes. Theoretically, the high density arrays (e.g., 500K probes) with an average 10 probes per call allow for a resolution of around 50K but arrays with even higher numbers of probes can decrease the minimal detectable size of a deletion to around 25Kb 26 .
However, it appears that increasing the density of the arrays from 250-500k does not necessarily result in a higher detection rate for both microdeletions or UPD 34 . Examples of types of chromosomal lesions detectable by SNP-A are shown in Figure 5 . In oligo-CGH-A, because probe spacing does not depend upon the location of SNPs, probes can be evenly distributed, allowing for median probe spacing (e.g., in 385K arrays is every 6Kb). In addition, CGH-A targeting individual chromosomes allow for an even higher resolution which enables mapping of break points within 05Kb intervals.
In SNP-A, there is an expected variability in the minimal size of the area of LOH that can be detected, with regions of >200Kb having a high chance of detection while <50Kb LOH segments are less reliably identified constitutional DNA, although to a degree, it can perhaps be inferred from the size of the affected region. Somatic UPD was first identified using microsatellites and has been found in several malignancies and many distinct chromosomal locations. The first detection of acquired UPD in hematological disorders was in polycythemia vera (PV) 38 , a discovery that paved the way for subsequent discovery of the V617F JAK2 mutation 39 . However, systematic studies with precise mapping of regions affected by UPD were not performed until SNP-A became available. The utility of DNA arrays to conveniently detect UPD in AML was initially reported in a study of 60 AML patients using 10K arrays 40 . Regions of homozygosity likely representing somatic UPD were identified in 12% of cases. SNP-A also allowed for very efficient identification UPD9p 28;41 . By analogy to this lesion, UPD in other areas of the genome can indicate the presence of activating mutations in important genes, e.g., homozygous mutation in CEBPA (19q) 42 or UPD13q and Flt-3 mutations 40 (see also below). Similarly, as inactivating NF-1 mutation in a homozygous constellation was found in patients with JMML with UPD17q 43 ( Table 2 ). The presence of biallelic mutations such as in cases of AML with Flt-3 ITD may be associated with worse prognostic features as compared to heterozygous genotypes 44 .
The pathophysiology of UPD may include various mechanisms, several shared with deletions. Somatic UPD may result in duplication of an activating somatic mutation or homozygosity for a disease-prone minor allele present in the germ line. UPD can also result in increased or decreased gene expression due to duplication of a methylation pattern. A similar mechanism may operate in deletion with loss of the inactivated or unmethylated allele. In addition,
9
For personal use at PENN STATE UNIVERSITY on February 27, 2013. bloodjournal.hematologylibrary.org From deletion may result in haploinsufficiency or loss of the intact allele with the remaining allele deficient due to somatic polymorphism or an inactivating somatic mutation.
The presence of somatically-acquired UPD as a clonal marker has to be evaluated in the context of corresponding normal tissues. Smaller areas of UPD involving limited numbers of SNPs are more frequent and may not be a result of germ line mitotic recombination or autozygosity but due to the variability of the normal distribution of heterozygous calls 25 . In some individuals, larger regions can be affected by UPD; in the Hapmap project 15% of control individuals showed areas of homozygosity, all smaller than 2Mb 34 . These regions are unlikely to correspond to somatic UPD and are germ line-encoded. In controls used for the SNP-A study in MDS, 72% of samples contained areas of homozygosity, but most of the changes were small and non-clonal UPD regions >2 MB were found only in 12% of cases 34, 33 . Similarly, areas of shared homozygosity were found both in blood samples and isolated myeloma cells in 2 of 12 cases, implying that this UPD may be non-clonal and can involve even whole arms of chromosomes in the germ line configuration 45 . While it is likely that some smaller areas resembling UPD are a technical artifact or autozygosity, the large numbers of consecutive SNPs in homozygous configuration found in controls suggest true germ line UPD.
The detection rate depends on the distance between the SNPs, size of the region and the numbers of SNPs. As a consequence, the minimum detectable length of copy-neutral LOH decreases with a higher density of SNP-A
46
. While we observed germ line-encoded UPD as large as 18Mb, as a general rule, larger regions of UPD are less likely to be of germ-line origin and point towards a clonal event 33 .
In conclusion, comparison of tumor and paired constitutional samples is necessary to identify a truly somatic event in the cases of any new copy-neutral LOH that does not affect the invariant areas of genome known to be pathologic. Of note is that the sensitivity of SNP-
A for deletions and UPD may differ and depends both on the computational algorithms as well as the density of the arrays. In one study, as few as 20% of clonal cells in the sample allowed for a clear identification of somatic UPD 47 .
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In addition to its diagnostic value, whole genome scanning-based karyotyping constitutes an excellent mapping tool, thereby allowing for delineation of boundaries of commonly deleted/duplicated regions or, in the case of SNP-A, areas of segmental UPD overlap (Figure 8) .
Moreover, genotyping arrays can be used for genotypic analysis within areas of UPD. Changes in the heterozygous genotype in the germ line configuration to hemi-(deletion) or homozygosity (UPD) may point towards causative genes, in the case of minor alleles with an exceedingly low homozygous frequency in the general population. Further improvement of mapping is possible using multiple sample analysis algorithms assigning either an average intensity (copy number) or a combined LOH genotyping score over a region of interest across multiple samples 36 .
Comparison of whole genome scanning technologies as a karyotyping tool with other methods. Overall, SNP-A allows for detection of unbalanced cytogenetic defects and UPD in non-dividing cells and assesses distribution of cytogenetic defects among all cells, not only in dividing progenitors. Its sensitivity is comparable to that of metaphase cytogenetics. In contrast,
SNP-A arrays demonstrate excellent resolution and also allows, unlike CGH-A, the detection of UPD.
Comparison between SNP-A, high-density BAC CGH-A and oligo-CGH-A showed comparable results but clearly bioinformatic tools influence the data output. It appears that oligo-CGH can achieve the best resolution and precision in identifying copy number changes, including CNVs 48;49 ( Table 1) .
Implications of array-based karyptyping in hematologic diseases.
Myelodysplastic syndromes. Early studies employed BAC CGH for the investigation of genomic changes in various solid tumors and hematopoietic malignancies, including MDS [50] [51] [52] [53] [54] .
CGH-A allowed for a wider application of this technology than very labor intense chromosomal CGH 55 . The quality of CGH-A-based analysis is limited by the platform on which it is performed and depends on the density of BAC probes, varying from thousands to hundreds of thousands 26 .
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For In general, investigations performed with 250K and 50K arrays suggested that SNP-Adetected lesions, including UPD, may have clinical relevance and can effectively "upgrade" the IPSS score to more advanced disease. For example, in a recent study of MPD and MDS/MPD patients, UPD9 was easily identified using SNP arrays but UPD6 and UPD11 was also frequently detected. In particular, UPD11q was frequently encountered in patients with CMML. Previously, in JMML a large region of UPD17q was found in cases with NF-1 mutation 43 . Similarly, invariant UPD on 4q was identified in 25% of RARS, 12% of RCMD with normal cytogenetics, 17% of RAEB, and 6% of 5q-syndrome cases 34 . In addition, more complex defects appear to be more frequent and include both UPD of various chromosomes and deletions. Another conclusion that can be derived from SNP-A-based analysis of AA is that submicroscopic cytogenetic defects can be used as markers of clonaliy and in some cases provide a distinction between hypocellular MDS (abnormal SNP-A cytogenetics) from a typical AA 16 . For personal use at PENN STATE UNIVERSITY on February 27, 2013. bloodjournal.hematologylibrary.org From of UPD may point towards genes harboring mutations as duplication of the mutated allele may provide selection advantage to the affected clone. Later studies showed that SNP-A can provide insights into the origin of AML transformation in MPD. Upon transformation to AML, serially studied patients showed evolution of AML either from JaK2V617F+ (with UPD9 present in the blast population and in granulocytes prior to and after transformation) or Jak2V617F-hematopoietic clone (UPD9 present in granulocytes but not in AML blasts) with appearance of new additional lesions, e.g., UPD7, UPD6 or del7 41 . This result is in agreement with other studies of MPD-derived AML showing that AML may evolve from a Jak2V617F-precursor and only less frequently from the original Jak2 mutation-containing clone 64 and is consistent with low incidence of Jak2 mutations in AML [65] [66] [67] . In a study of patients with MDS-derived secondary AML, UPD of various chromosomes was found in 23% and additional lesions conveyed shorter survival Similar to AML, CGH-A-based karyotyping allows for improving the detection rate of chromosomal abnormalities over MC in ALL (e.g., copy number changes in 73% of cases) 68;69 .
AML and ALL. Both SNP-A and oligo CGH-
When oligo-CGH-A was applied to study ALL, various previously undetected lesions were found.
Among them, deletions of various sizes involving chromosome 9p were detected in 46% of patients 14 only.
For personal use at PENN STATE UNIVERSITY on February 27, 2013. bloodjournal.hematologylibrary.org From with the CDR involving the CDKN2A gene 70 . Similar deletions of 9p21 were observed in another study utilizing high-resolution BAC CGH-A which also allowed for detection of gains in 1q23-qter in low-risk and 2p11.2 in high-risk disease 71 . In two other studies, intra-chromosomal 21q amplifications involving RUNX1 were found 72;73 . Of particular importance is that CGH-A allowed for detection of cytogenetic abnormalities in patients with normal or failed MC . Similarly, high-resolution 10K and 50K Affymetrix SNP-
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A were evaluated as a diagnostic tool for CLL and revealed chromosomal imbalances in 66% of 70 consecutive cases 45 . Among the prognostically-important aberrations, del13q14 was present in 36 (51.4%), trisomy 12 in 9 (12.8%), del11q22 in 9 (12.8%), and del17p13 in 4 cases (5.7%). A prominent clustering of breakpoints on both sides of the MIRN15A/MIRN16-1 genes indicated the presence of recombination hot spots in the 13q14 region. Patients with a monoallelic del13q14 had slower lymphocyte growth kinetics than patients with bi-allelic deletions 45 . UPD regions with loss of heterozygosity were identified in 14 cases and, similar to the findings in MDS with UPD7q, 6q or 11q, corresponded to areas frequently affected by deletions. Of note is that some of the controls also contained copy-neutral UPD and comparison with germ line DNA suggested some of the UPD may not be a somatic event 45 . In another study, cytogenetic changes were investigated in 56 CLL patients using 50K SNP-A which confirmed nearly all changes detected by FISH. Moreover, new abnormalities were found, including UPD in 4/46 patients 78 
.
In MM, a number of prognosticaly important chromosomal abnormalities can be detected using SNP-A. In the initial study utilizing 50K SNP-A involving 30 MM patients and purified plasma cells, a large number of of deletions and gains were reported 79 . MC showed cytogenetic abnormalities in 44% of cases studied, while using SNP-A chromosomal defects were found in most of the patients. UPD was identified at a large frequency in most of the patients, showing up to 19 regions of UPD per patient. However, most of these lesions were small and, in view of the fact that the confirmation through comparison with germ line samples was not given, not all of these lesions represented true somatic events.
When 500K SNP-A were applied to study the karyotypes of 55 MM cases 80 , many of the known lesions, e.g., involving chromosome 16, were found and, by analogy to the findings in MDS, also included UPD, such as UPD16, present in 75% of patients. SNP-A analysis allowed for precise mapping of the lesions and delineation of commonly deleted region. Expression analysis of genes contained in the CDR was used to identify 2 genes with a significantly decreased expression in CLL, including WWOX and CYLD. Haploinsuffciency of these genes provides molecular insights 16 only.
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Conclusions.
Whole genome scanning technology has ushered in a new era in the detection of genomic defects in malignant disease and has led to a markedly increased resolution of karyotyping. It is likely that this technology will be introduced into the clinical practice to complement MC. Its For personal use at PENN STATE UNIVERSITY on February 27, 2013. bloodjournal.hematologylibrary.org From mutation, acquired homozygosity of a germ line-encoded polymorphism occurring normally in heterozygous form, or duplication of maternal or paternal methylation pattern with either activation or total inactivation of the duplicated allele. In deletion, the remaining allele may harbor a somatic inactivating mutation, leading to hemizygosity of a germ line polymorphism that carries functional consequences or haploinsufficiency. 
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